Are Stereotactic Body Radiotherapy and Zoledronic Acid Combination Additive or Synergistic in Bone Metastasis?

Year 2020, , 84 - 86, 26.08.2020

Yasemin Benderli Cihan

https://doi.org/10.26650/experimed.2020.0013

Abstract

Bone metastasis is an important cause of morbidity and mortality. In today's oncology practice, zoledronic acid (ZA) and Stereotactic Body Radiotherapy (SBRT) have been widely used in the treatment of bone metastases and in the treatment of bone pain reduction. Whether this combined therapy is additive or synergistic is not yet known. There are not enough studies on this subject yet. To better understand the effects of ZA and SBRT combination therapy, prospective studies including more patients are needed.

Keywords

Bone metastasis, SBRT, zoledronic acid

SBRT ve Zoledronik Asid Kombinasyonu Kemik Metastaz Tedavisinde Aditif veya Sinerjistik Etki Mi Yapar?

Abstract

Kemik metastazı önemli bir morbidite ve mortalite nedenidir. Günümüz onkoloji pratiğinde zoledronik asit ve stereotaktik vücut radyoterapisi (SBRT), kemik metastazlarının tedavisi ve kemik ağrılarının azaltılması tedavisinde yaygın olarak kullanılmaya başlanılmıştır. Bu kombine tedavinin aditif veya sinerjistik etki yapıp yapmadığı henüz bilinmemektedir. Bu konuda henüz yeterli çalışma bulunmamaktadır. Zoledronik asit ve SBRT kombinasyon tedavisinin etkilerinin daha iyi anlaşılabilmesi için prospektif ve daha çok sayıda hastayı içeren çalışmalara ihtiyaç vardır.

Keywords

Kemik metastazı, SBRT, zoledronik asit

References

• 1. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012; 2:CD003474. [CrossRef]
• 2. O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2017; 30: CD003474. [CrossRef]
• 3. Sarhan D, Leijonhufvud C, Murray S, Witt K, Seitz C, Wallerius M, et al. Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer. Oncoimmunology 2017; 14; 6(8): e1338238. [CrossRef]
• 4. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kurado J, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005; 116(1): 94-9. [CrossRef]
• 5. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases andproinflammatory cytokines in metastatic breast cancer patients. Oncology 2005; 69(1): 35-43. [CrossRef]
• 6. Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004; 45: 521-8. [CrossRef]
• 7. Chuah C, Barnes DJ, Kwok M, Corcin A, Deininger MWN, Druker BJ, et al. Zoledronate inhibits proliferation and induces apoptosis of imatinib resistant chronic myeloid leukaemia cells. Leukemia 2005; 19(11): 1896-904. [CrossRef]
• 8. Winter MC, Thorpe HC, Burkinshaw R, Beevers SJ, Coleman RE. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response exploratory evidence for direct antitumour activity in breast cancer. Cancer Res 2009; 69. [CrossRef]
• 9. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L. Longterm efficiacy of zoledronic acid fort he prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-82. [CrossRef]
• 10. Du C, Wang Y, Li H, Huang Y, Jiang O, You Y, et al. Zoledronic acid augments the radiosensitivity of cancer cells through perturbing S- and M-phase cyclins and p21CIP1 expression. Oncol Lett 2017; 14(4): 4237-42. [CrossRef]
• 11. Pichon B, Campion L, Delpon G, Thillays F, Carrie C, Cellier P, et al. High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study. Int J Radiat Oncol Biol Phys 2016; 96(4): 840-7. [CrossRef]
• 12. Lu CW, Shao J, Wu YG, Wang C, Wu JH, Lv RX, et al. Which Combination Treatment Is Better for Spinal Metastasis, Percutaneous Vertebroplasty With Radiofrequency Ablation, 125I Seed, Zoledronic Acid, or Radiotherapy? Am J Ther 2019; 26(1): e38-e44. [CrossRef]